Cancer
Malignant Cervical Neoplasm
CI-CAN-00007992Explore in graph →
Top-level506 active trials4 approved drugs14 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00007992Explore in graph →
Clinical trials
1,994 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (181)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07226037 | Development of Systems and Education for Cervical Cancer Prevention (DOSE-CC)(DOSE-CC) | not yet recruiting | N/A | 80,000 | Boston Medical CenterOTHER | 0 | Nov 10, 2025 | clinicaltrials |
| NCT01676818 | Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical Cancer | completed | Phase 2 | 32 | University of Southern CaliforniaOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT06677190 | Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin | recruiting | Phase 2 | 32 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 5, 2025 | clinicaltrials |
| NCT02111941 | Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | completed | Early Phase 1 | 19 | Mayo ClinicOTHER | 1 | Oct 31, 2025 | clinicaltrials |
| NCT03452774 | SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | recruiting | — | 50,000 | Massive Bio, Inc.INDUSTRY | 2 | Oct 28, 2025 | clinicaltrials |
| NCT04574635 | Human Papilloma Virus (HPV) Circulating Tumor DNA (ctDNA) in Cervical Cancer | active not recruiting | — | 18 | Mayo ClinicOTHER | 1 | Oct 27, 2025 | clinicaltrials |
| NCT06861504 | The Femscope Calm Collect Device | completed | N/A | 13 | University of MichiganOTHER | 1 | Oct 27, 2025 | clinicaltrials |
| NCT05512208 | A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib(DURAFAK) | recruiting | Phase 2 | 55 | University of OklahomaOTHER | 1 | Oct 22, 2025 | clinicaltrials |
| NCT04049227 | Abemaciclib and Letrozole in Treating Patients With Endometrial Cancer | completed | Early Phase 1 | 27 | Northwestern UniversityOTHER | 1 | Oct 20, 2025 | clinicaltrials |
| NCT04272034 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors | terminated | Phase 1 | 105 | Incyte CorporationINDUSTRY | 7 | Oct 16, 2025 | clinicaltrials |
| NCT05247853 | HPV Vaccine Effectiveness Study in Rwandan Women Living With HIV | completed | — | 3,127 | Montefiore Medical CenterOTHER | 1 | Oct 16, 2025 | clinicaltrials |
| NCT04363957 | Gynecologic Brachytherapy-Specific Educational Video | completed | N/A | 80 | University of California, San DiegoOTHER | 1 | Oct 14, 2025 | clinicaltrials |
| NCT06577220 | Prospective Evaluation of Self-Testing to Increase Screening (PRESTIS) Asian/Asian American Women Supplement | active not recruiting | N/A | 111 | Baylor College of MedicineOTHER | 1 | Oct 14, 2025 | clinicaltrials |
| NCT07213427 | Outcomes of Image-guided High-dose-rate Uterovaginal Brachytherapy With Single Implantation(UNICURE-HD) | not yet recruiting | — | 363 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Oct 8, 2025 | clinicaltrials |
| NCT01935934 | Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer | completed | Phase 2 | 102 | National Cancer Institute (NCI)NIH | 2 | Oct 1, 2025 | clinicaltrials |
| NCT04512144 | Mindfulness in Endometrial and Cervical Cancer(MECCA) | recruiting | N/A | 120 | St. Louis UniversityOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT04111978 | MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)(MATAO) | recruiting | Phase 3 | 540 | Swiss GO Trial GroupNETWORK | 3 | Sep 29, 2025 | clinicaltrials |
| NCT05990803 | A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies | recruiting | Phase 2 | 130 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT05197881 | Daily Adaptive Radiation Therapy an Individualized Approach for Carcinoma of the Cervix(ARTIA-Cervix) | recruiting | N/A | 125 | Varian, a Siemens Healthineers CompanyINDUSTRY | 1 | Sep 23, 2025 | clinicaltrials |
| NCT05606133 | Circulating Human Papilloma Virus (HPV) DNA for the Screening and Surveillance of Gynecologic Cancers | recruiting | N/A | 100 | Northwell HealthOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT02628067 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | active not recruiting | Phase 2 | 1,609 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 22, 2025 | clinicaltrials |
| NCT07088731 | Clinical Study to Evaluate the Efficacy and Safety of Nab-Paclitaxel Combined With Cisplatin and Sintilimab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer | not yet recruiting | Phase 2 | 180 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT07186868 | QL706 + Chemo ± Bevacizumab in Anti-PD-(L)1-Resistant R/M Cervical Cancer | not yet recruiting | — | 25 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Sep 22, 2025 | clinicaltrials |
| NCT03298893 | Nivolumab in Association With Radiotherapy and Cisplatin in Locally Advanced Cervical Cancers Followed by Adjuvant Nivolumab for up to 6 Months (NiCOL)(NiCOL) | completed | Phase 1 / Phase 2 | 21 | Institut CurieOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT05133661 | SUCCESS - Feasibility of HPV Testing and Treatment of Pre-cancerous Cervical Cancer Lesions (HPV Study)(HPV) | active not recruiting | — | 17,602 | JhpiegoOTHER | 4 | Sep 17, 2025 | clinicaltrials |
| NCT05736588 | Elimisha HPV (Human Papillomavirus) | completed | N/A | 982 | Duke UniversityOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT06942286 | Primary HPV Self-Collection in Indonesia | enrolling by invitation | N/A | 8,000 | Dharmais National Cancer Center HospitalOTHER_GOV | 1 | Sep 17, 2025 | clinicaltrials |
| NCT07177716 | Efficacy and Safety of LB1410 Plus Lenvatinib With or Without LB4330 in Advanced Recurrent/Metastatic Cervical Cancer | not yet recruiting | Phase 2 / Phase 3 | 120 | L & L Bio Co., Ltd., Ningbo, ChinaINDUSTRY | 1 | Sep 17, 2025 | clinicaltrials |
| NCT03958240 | Deciphering Mechanisms Underlying Cancer Immunogenicity(DECIDE) | recruiting | N/A | 1,100 | Institut Claudius RegaudOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT07172217 | The Efficacy and Safety RC48 Plus QL1706 in Second-Line Treatment of HER2-Expressing Recurrent CC | not yet recruiting | Phase 2 | 33 | Qilu Hospital of Shandong UniversityOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT07055399 | Neoadjuvant Iparomlimab and Tuvonralimab Plus Chemotherapy-eclipse for Locally Advanced Cervical Cancer (NICE-CC)(NICE-CC) | recruiting | Phase 2 | 43 | Fujian Cancer HospitalOTHER_GOV | 1 | Sep 11, 2025 | clinicaltrials |
| NCT04411849 | Multilevel HPV Self-Testing Intervention for the Increase of Cervical Cancer Screening Among Women in Appalachia | completed | N/A | 802 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT04906993 | Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer | active not recruiting | Phase 3 | 443 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT05107674 | A Study of NX-1607 in Adults With Advanced Malignancies | recruiting | Phase 1 | 345 | Nurix Therapeutics, Inc.INDUSTRY | 2 | Sep 9, 2025 | clinicaltrials |
| NCT02554565 | Innovation for Standard Identification of Insertional HPV Mutations and of Target Therapeutic Genes in Cervical Cancer: Towards Development of Personalized Biomarkers in Clinical Oncology (PAIR HPV)(PAIR HPV) | terminated | N/A | 26 | Institut CurieOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT04534075 | Dietary Fiber During Radiotherapy - a Placebo-controlled Randomized Trial(FIDURA) | completed | Phase 3 | 354 | Sahlgrenska University HospitalOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT04646005 | Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy | completed | Phase 2 | 113 | Regeneron PharmaceuticalsINDUSTRY | 8 | Sep 8, 2025 | clinicaltrials |
| NCT00924027 | A Study of Patients Receiving High-Dose Rate Brachytherapy | completed | Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Sep 5, 2025 | clinicaltrials |
| NCT05462379 | Autologous Heterotopic Fresh Ovarian Graft in Woman With LACC Eligible for Pelvic Radiotherapy Treatment. | active not recruiting | Phase 1 / Phase 2 | 22 | MARILIA ALBANEZI BERTOLAZZIOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT05742711 | Efficacy of PENS of the Auricle as an Opioid Sparing Postoperative Analgesic Technique in Cancer Endometrium and Cancer Cervix Patients | completed | N/A | 48 | DyAnsys, Inc.INDUSTRY | 1 | Sep 5, 2025 | clinicaltrials |
| NCT03180034 | Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO Study(ESCUDDO) | active not recruiting | Phase 4 | 27,945 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2025 | clinicaltrials |
| NCT03898167 | Prospective Evaluation of Self-Testing to Increase Screening(PRESTIS) | completed | N/A | 2,474 | Baylor College of MedicineOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT07153952 | RT for Adenocarcinoma/Adenosquamous Carcinoma | active not recruiting | Phase 1 / Phase 2 | 60 | Peking Union Medical College HospitalOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT04555226 | The Efficacy of Lymph Node Dissection for Stage IIICr of Cervical Cancer(CQGOG0103) | recruiting | N/A | 452 | Chongqing University Cancer HospitalOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT03300557 | Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Aug 29, 2025 | clinicaltrials |
| NCT04772989 | A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies(ARC-12) | completed | Phase 1 | 94 | Arcus Biosciences, Inc.INDUSTRY | 3 | Aug 28, 2025 | clinicaltrials |
| NCT06582849 | Enhanced Assistance During Radiotherapy for Unmet Essential Needs(EARN) | completed | N/A | 33 | Washington University School of MedicineOTHER | 1 | Aug 26, 2025 | clinicaltrials |
| NCT07141186 | QL1706 in Patients With Recurrent and Metastatic Cervical Cancer Resistant to Prior PD-1/PD-L1 Antibody Therapy | not yet recruiting | Phase 2 | 50 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Aug 26, 2025 | clinicaltrials |
| NCT05105087 | Gynecological Sentinel Lymph Nodes CEUS | completed | Early Phase 1 | 9 | Thomas Jefferson UniversityOTHER | 1 | Aug 22, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Nov 10, 2025source: clinicaltrials